Masimo Geçmiş Kazanç Performansı
Geçmiş kriter kontrolleri 5/6
Masimo şirketinin kazançları yıllık ortalama -32.3% oranında azalırken, Medical Equipment sektörünün kazançları yıllık 13.6% oranında artan oldu. Gelirler yıllık ortalama 5.8% oranında artan oldu. Masimo şirketinin öz sermaye getirisi 27.5% olup, net marjı 13.9% dir.
Anahtar bilgiler
-32.28%
Kazanç büyüme oranı
-31.48%
EPS büyüme oranı
| Medical Equipment Sektör Büyümesi | 8.90% |
| Gelir büyüme oranı | 5.75% |
| Özkaynak getirisi | 27.48% |
| Net Marj | 13.91% |
| Son Kazanç Güncellemesi | 04 Apr 2026 |
Yakın geçmiş performans güncellemeleri
Recent updates
Anlatı Güncellemesi • May 12
MASI: Cash Deal Terms And Legal Outcomes Will Shape Future Returns
Analysts held Masimo's fair value estimate steady at $180 per share, with only small tweaks to discount rate, growth, margin, and P/E assumptions as they factor in the agreed $180 per share cash acquisition by Danaher and recent shifts in research coverage and ratings. Analyst Commentary Recent research coverage on Masimo has shifted toward a more balanced stance after the agreed cash acquisition by Danaher at US$180 per share, with several firms resetting ratings and price targets around the deal terms.Anlatı Güncellemesi • Apr 23
MASI: Danaher Cash Offer And Legal And Deal Completion Risks Will Dominate
The analyst fair value estimate for Masimo has been adjusted from $177 to $180, with analysts pointing to the agreed $180 per share cash acquisition by Danaher as the key anchor for updated price targets and ratings. Analyst Commentary Recent research on Masimo has shifted from growth driven valuation debates to a focus on the agreed US$180 per share cash offer from Danaher as the primary reference point for fair value and ratings.Anlatı Güncellemesi • Apr 09
MASI: Danaher Cash Offer And Legal Outcomes Will Steer Deal Path
The analyst price target for Masimo has been trimmed by about $1.60 to $177.00, as analysts factor in a slightly higher discount rate and a modestly lower future P/E, while aligning expectations with the $180 per share cash acquisition offer from Danaher. Analyst Commentary Recent research on Masimo has become highly focused on the agreed cash acquisition by Danaher at $180 per share, with most coverage shifting from long term growth narratives to deal related outcomes and near term valuation anchor points.Anlatı Güncellemesi • Mar 25
MASI: Danaher Cash Offer And Patent Rulings Will Shape Deal Outcome
Analysts kept Masimo's fair value estimate steady at $178.60 while aligning their price targets around the agreed $180 per share cash acquisition by Danaher, with recent rating changes reflecting the view that any potential upside is now largely tied to the deal closing as planned. Analyst Commentary Recent research on Masimo centers on the agreed US$180 per share cash offer from Danaher, with ratings and targets now clustered around that level.Anlatı Güncellemesi • Mar 05
MASI: Danaher Cash Deal And Legal Overhang Will Frame Future Returns
The updated analyst price target for Masimo edges down by $0.15 to $178.60, as analysts anchor their views to Danaher's agreed $180 per share cash acquisition and recent rating moves to Neutral or No Rating. Analyst Commentary Recent research around Masimo has centered on the agreed US$180 per share cash acquisition by Danaher, with most analysts reframing their views around deal completion rather than standalone upside or downside.Anlatı Güncellemesi • Feb 18
MASI: Danaher Cash Buyout Will Define Future Returns And Key Risks
Analysts have trimmed their Masimo fair value estimate from $183.13 to $178.75 to align expectations with the agreed $180 per share cash acquisition by Danaher. This shift is reflected in new Hold and Neutral ratings that are centered around the $180 level.Seeking Alpha • Feb 17
Masimo: Danaher Acquisition Saves The Company From Lackluster Performance
Summary Masimo Corporation agreed to be acquired by Danaher for $180/share, valuing MASI at $9.9B. The acquisition offers a strong strategic fit, combining MASI's non-invasive oximetry with DHR's invasive diagnostics for comprehensive acute care solutions. Shareholders benefit from a 34% stock price surge and a potential 2.8% spread to deal close, with minimal market risk. Holding MASI shares until the deal closes offers a relatively safe, low-stress return, though opportunity cost and regulatory risk remain. Read the full article on Seeking AlphaAnlatı Güncellemesi • Nov 21
MASI: Renewed Philips Partnership Will Drive Outperformance Despite Market Challenges
Analysts have adjusted their price target for Masimo downward from approximately $188 to $183. This change is attributed to shifts in revenue growth estimates and a strengthening profit margin following recent partnership developments and ongoing market challenges.Analiz Makalesi • Sep 12
Is Masimo Corporation (NASDAQ:MASI) Potentially Undervalued?
Masimo Corporation ( NASDAQ:MASI ), might not be a large cap stock, but it received a lot of attention from a...Analiz Makalesi • Aug 01
Calculating The Fair Value Of Masimo Corporation (NASDAQ:MASI)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Masimo fair value estimate is US$136 Masimo's US$154 share...Analiz Makalesi • Jun 19
Is Masimo (NASDAQ:MASI) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Analiz Makalesi • May 29
Is It Time To Consider Buying Masimo Corporation (NASDAQ:MASI)?
Masimo Corporation ( NASDAQ:MASI ), is not the largest company out there, but it saw significant share price movement...Seeking Alpha • Apr 25
Masimo: Priced Dearly Given Uncertainty
Summary Masimo Corporation, a mid-cap healthcare firm, has a new CEO and is navigating considerable uncertainty. Some aspects of the company's divestiture of its consumer business are still unclear. Despite this, the stock is generally well liked within the analyst firm community, following solid Q4 results. An analysis around Masimo Corporation follows in the paragraphs below. Read the full article on Seeking AlphaSeeking Alpha • Dec 11
Masimo: A Stellar Performance After The Dust Has Settled
Summary Masimo's proxy fight and Sound United acquisition distracted from the core business, but resolution and focus on healthcare are driving value and momentum. Shares surged over 50% since July due to strong Q2 results and improved earnings guidance, despite ongoing challenges and leadership changes. Current valuations are demanding, suggesting an opportune time for profit taking, while I maintain a position for long-term growth potential. Divesting Sound United could reduce debt, enhancing focus on the core med-tech business with promising double-digit organic growth. Read the full article on Seeking AlphaSeeking Alpha • Sep 25
Masimo Corporation: Too Much Uncertainty For Now
Summary Masimo Corporation's stock has underperformed, with shares down 6% versus SPY's 15% increase, due to mixed margins and lack of meaningful catalysts. The company's financials show low ROA, ROE, and ROTC, with tight margins and a concerning interest coverage ratio of 2.6x. The sale of Sound United and recent partnerships with Google and Qualcomm offer potential, but the future growth sustainability remains uncertain. Internal management struggles and recent board shakeup add to the volatility, making me cautious and opting to stay on the sidelines for now. Read the full article on Seeking Alpha
Yeni Anlatı • Aug 28
Sensors Surge And Decisive Shifts Set To Soar In Healthcare Triumph
Increased hospital admissions and successful hospital conversions to Masimo products are anticipated to continue driving healthcare revenue growth.Gelir ve Gider Dağılımı
Gelir ve Gider Dağılımı
Masimo nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.
Kazanç ve Gelir Geçmişi
| Tarih | Gelir | Kazançlar | G+A Giderleri | Ar-Ge Giderleri |
|---|---|---|---|---|
| 04 Apr 26 | 1,559 | 217 | 517 | 123 |
| 03 Jan 26 | 1,527 | 208 | 511 | 126 |
| 27 Sep 25 | 2,182 | -240 | 749 | 203 |
| 28 Jun 25 | 2,154 | -270 | 770 | 210 |
| 29 Mar 25 | 1,428 | 31 | 516 | 142 |
| 28 Dec 24 | 1,395 | 16 | 518 | 146 |
| 28 Sep 24 | 1,576 | 115 | 538 | 152 |
| 29 Jun 24 | 1,711 | 101 | 558 | 161 |
| 30 Mar 24 | 1,823 | 92 | 588 | 163 |
| 30 Dec 23 | 1,276 | 108 | 451 | 131 |
| 30 Sep 23 | 2,116 | 89 | 690 | 192 |
| 01 Jul 23 | 2,187 | 116 | 707 | 198 |
| 01 Apr 23 | 2,297 | 118 | 728 | 206 |
| 31 Dec 22 | 2,036 | 144 | 641 | 191 |
| 01 Oct 22 | 1,746 | 171 | 559 | 170 |
| 02 Jul 22 | 1,505 | 191 | 487 | 153 |
| 02 Apr 22 | 1,244 | 223 | 408 | 139 |
| 01 Jan 22 | 1,239 | 230 | 395 | 137 |
| 02 Oct 21 | 1,207 | 232 | 382 | 136 |
| 03 Jul 21 | 1,177 | 224 | 371 | 129 |
| 03 Apr 21 | 1,173 | 229 | 376 | 126 |
| 02 Jan 21 | 1,144 | 240 | 369 | 119 |
| 26 Sep 20 | 1,096 | 223 | 361 | 110 |
| 27 Jun 20 | 1,047 | 222 | 351 | 106 |
| 28 Mar 20 | 976 | 211 | 330 | 99 |
| 28 Dec 19 | 938 | 196 | 315 | 93 |
| 28 Sep 19 | 913 | 190 | 306 | 91 |
| 29 Jun 19 | 895 | 198 | 297 | 87 |
| 30 Mar 19 | 877 | 197 | 289 | 83 |
| 29 Dec 18 | 858 | 194 | 285 | 81 |
| 29 Sep 18 | 843 | 139 | 290 | 76 |
| 30 Jun 18 | 826 | 118 | 284 | 71 |
| 31 Mar 18 | 807 | 119 | 280 | 67 |
| 30 Dec 17 | 790 | 125 | 273 | 65 |
| 30 Sep 17 | 766 | 348 | 271 | 60 |
| 01 Jul 17 | 740 | 340 | 263 | 61 |
| 01 Apr 17 | 720 | 325 | 260 | 59 |
| 31 Dec 16 | 713 | 311 | 255 | 58 |
| 01 Oct 16 | 672 | 109 | 255 | 58 |
| 02 Jul 16 | 657 | 101 | 257 | 57 |
| 02 Apr 16 | 640 | 90 | 254 | 55 |
| 02 Jan 16 | 623 | 83 | 253 | 56 |
| 03 Oct 15 | 623 | 80 | 244 | 58 |
| 04 Jul 15 | 613 | 76 | 246 | 58 |
Kaliteli Kazançlar: MASI yüksek kaliteli kazançlar sağlıyor.
Büyüyen Kar Marjı: MASI 'nin mevcut net kar marjları (13.9%) geçen yılın (0.8%) sinden daha yüksektir.
Serbest Nakit Akışı ve Kazanç Analizi
Geçmiş Kazanç Büyüme Analizi
Kazanç Eğilimi: MASI şirketinin kazançları son 5 yılda yılda 32.3% oranında azaldı.
Büyüme Hızlandırma: MASI 'un son bir yıldaki kazanç büyümesi ( 1792.8% ) 5 yıllık ortalamasını (yıllık -32.3% ) aşıyor.
Kazançlar vs. Sektör: MASI geçen yılki kazanç büyümesi ( 1792.8% ) Medical Equipment sektörünün 14.8% değerini aştı.
Özkaynak Getirisi
Yüksek ROE: MASI 'nin Özsermaye Getirisi ( 27.5% ) yüksek olarak değerlendiriliyor.
Varlık Getirisi
Kullanılan Sermaye Getirisi
Geçmişte güçlü performans gösteren şirketleri keşfedin
Şirket Analizi ve Finansal Veri Durumu
| Veri | Son Güncelleme (UTC saati) |
|---|---|
| Şirket Analizi | 2026/05/22 17:06 |
| Gün Sonu Hisse Fiyatı | 2026/05/22 00:00 |
| Kazançlar | 2026/04/04 |
| Yıllık Kazançlar | 2026/01/03 |
Veri Kaynakları
Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
| Paket | Veri | Zaman Çerçevesi | Örnek ABD Kaynağı * |
|---|---|---|---|
| Şirket Finansalları | 10 yıl |
| |
| Analist Konsensüs Tahminleri | +3 yıl |
|
|
| Piyasa Fiyatları | 30 yıl |
| |
| Sahiplik | 10 yıl |
| |
| Yönetim | 10 yıl |
| |
| Önemli Gelişmeler | 10 yıl |
|
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi
Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri
Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.
Analist Kaynakları
Masimo Corporation 22 Bu analistlerden 6, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
| Analist | Kurum |
|---|---|
| Michael Polark | Baird |
| Charley Jones | Barrington Research Associates, Inc. |
| Ravi Misra | Berenberg |